SRPT Sarepta Therapeutics Inc.

101.07
+7.45  (+8%)
Previous Close 93.62
Open 98.28
Price To Book 9.61
Market Cap 7,860,899,054
Shares 77,776,779
Volume 954,547
Short Ratio
Av. Daily Volume 907,373
Stock charts supplied by TradingView

NewsSee all news

  1. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2020 that were previously

  2. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2020 that were previously

  3. Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program

    -- The Company will award up to 20 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy -- CAMBRIDGE, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the

  4. Antisense Therapeutics Announces Appointment of US-based Consultant Medical Director

    Clinician with deep experience in DMD drug development (ex-Sarepta Therapeutics Director) On the ground presence in the US to accelerate development activities Initial focus on engagement with Key Opinion Leaders

  5. Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments

    CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the three and twelve months

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Rolling NDA to be completed 2Q 2020.
Casimersen
Duchenne muscular dystrophy
Phase 1/2 ongoing.
rAAVrh74.MCK.GALGT2
Duchenne muscular dystrophy
Aims to have dosing and safety insight by mid-2020.
SRP-5051 - PPMO
Duchenne muscular dystrophy
FDA Approval announced December 12, 2019.
Golodirsen - Exon 53
Duchenne muscular dystrophy
Approved September 19, 2016.
Eteplirsen - Exon 51
Duchenne muscular dystrophy
Phase 1 trial ongoing.
MYO-201
Duchenne muscular dystrophy - (LGMD2B)
Phase 1/2 complete.
MYO-102
Duchenne muscular dystrophy - LGMD2D
Expression and safety data due 2Q 2020. Dose selection decision due 3Q 2020.
MYO-101 (SRP-9003)
Duchenne muscular dystrophy - LGMD2E
Phase 2/3 dosing to be completed mid-2020.
LYS-SAF302
Mucopolysaccharidosis type IIIA (MPS IIIA)
Phase 2 data due 1Q 2021.
SRP-9001
Duchenne muscular dystrophy
Phase 3 open-label data to be released March 2020. Overdue. No update from company so moved to 2Q 2020.
Eteplirsen (PROMOVI)
Duchenne Muscular Dystrophy (DMD)

Latest News

  1. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2020 that were previously

  2. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2020 that were previously

  3. Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program

    -- The Company will award up to 20 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy -- CAMBRIDGE, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the

  4. Antisense Therapeutics Announces Appointment of US-based Consultant Medical Director

    Clinician with deep experience in DMD drug development (ex-Sarepta Therapeutics Director) On the ground presence in the US to accelerate development activities Initial focus on engagement with Key Opinion Leaders

  5. Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments

    CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the three and twelve months

  6. Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments on February 26, 2020

    CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2019 financial results

  7. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2020 that were previously

  8. Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors

    CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it has appointed John C. Martin, Ph.D., to its

  9. Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 38th

  10. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2019, that were previously

  11. Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001

    – Roche obtains the exclusive right to launch and commercialize SRP-9001 outside the United States – – At closing, Sarepta will receive an upfront payment of $1.15 billion, comprising $750 million in cash and $400

  12. Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy

    Roche obtains the exclusive right to launch and commercialize SRP-9001, Sarepta's investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy (DMD) outside the United States At closing, Roche will pay

  13. Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing

    CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has entered into an agreement with funds

  14. Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53

    -- VYONDYS 53 is Sarepta's second RNA exon-skipping treatment for DMD approved in the U.S. -- -- Commercial distribution of VYONDYS 53 in the U.S. will commence immediately -- -- Information for patients and clinicians

  15. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2019, that were previously

  16. Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies

    -- Agreement leverages StrideBio's novel, industry-leading, structure-driven capsid engineering platform and expands Sarepta's early stage gene therapy pipeline – -- Sarepta granted an exclusive license to four CNS

  17. Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments

    CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2019.

  18. Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference

    CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the

  19. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2019, that were previously

  20. Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019

    CAMBRIDGE, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2019 financial results after the

  21. Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

    -- Improvements on functional measures seen in all three participants -- -- Significant reduction in creatine kinase maintained over nine months -- -- Results follow positive and robust expression and biomarker data

  22. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2019, that were

  23. Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

    CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Friday, Oct. 4, 2019 at 8:00 a.m.

  24. CLASS ACTION UPDATE for CTST, JE, VAL and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested

  25. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    New York, New York--(Newsfile Corp. - September 8, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) ("Sarepta" or the "Company") of

  26. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of MMM, GTT, PS and SRPT

    CEDARHURST, N.Y., Sept. 06, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies.

  27. IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  28. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    New York, New York--(Newsfile Corp. - September 5, 2019) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)("Sarepta" or the "Company")

  29. IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  30. Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the recipients of Route 79, The Duchenne

  31. Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT)

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT) in the

  32. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    NEW YORK, Sept. 5, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT) of the

  33. CLASS ACTION UPDATE for JE, TWOU, EVH and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested

  34. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT) of the October

  35. SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: October 29, 2019

    NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta"

  36. Sarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the

  37. INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Sarepta Therapeutics, Inc.

    --(BUSINESS WIRE)--The law firm of

  38. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 30, 2019, that were previously

  39. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT).   Such investors are advised to

  40. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sarepta Therapeutics, Inc.

    NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Sarepta Therapeutics, Inc. ("Sarepta or "the Company") (NASDAQ:SRPT) concerning possible